700874-72-2 | 4-[2-(6-Methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$63.00	$45.00
5mg	95%	in stock	$79.00	$55.00
100mg	95%	in stock	$114.00	$80.00
250mg	95%	in stock	$187.00	$131.00
1g	95%	in stock	$480.00	$336.00

Description

• Catalog Number: AB44683
• Chemical Name: 4-[2-(6-Methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
• CAS Number: 700874-72-2
• Molecular Formula: C22H19N5O
• Molecular Weight: 369.4192
• MDL Number: MFCD12923319
• SMILES: Cc1cccc(n1)c1nn2c(c1c1ccnc3c1cc(cc3)C(=O)N)CCC2

Computed Properties

• Complexity: 585
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 2.4

Upstream Synthesis Route

4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide is a vital tool in chemical synthesis, serving as a key building block for the development of novel pharmaceutical compounds. This compound is particularly valuable in medicinal chemistry research due to its unique structural features, which allow for the manipulation of the pyrrolopyrazole and quinoline moieties to create diverse analogs with potentially enhanced biological activities. By incorporating this versatile intermediate into synthetic pathways, chemists can access a wide range of derivatives with varied pharmacological properties, making it a promising candidate for the design and optimization of drug candidates.

Literature

• Prenatal nicotine exposure intergenerationally programs imperfect articular cartilage via histone deacetylation through maternal lineage.

  Toxicology and applied pharmacology 20180801

• Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.

  Archives of toxicology 20180701

• Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

  Oncotarget 20180123

• Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.

  Journal of medicinal chemistry 20140522

• Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.

  Journal of medicinal chemistry 20080410